Toxic epidermal necrolysis associated with combination therapy of spironolactone and torsemide
Introduction: Dytor plus tablet is a fixed-dose combination of torsemide and spironolactone used for generalized edema. TEN is a serious, potentially life-threatening dermatological disorder.
Methods: Here we present a case report of a 47-year-old female who was on Dytor Plus (5/50 mg)therapy once daily for generalized edema; presented to dermatology outpatient department with chief complaints of multiple erosions over oral cavity, swelling of lips with scaling, redness and burning sensation in both eyes, multiple well defined mostly erythematous rashes over the entire body since 2 days.
Results: On examination, her vital signs were stable and lab results indicate she had elevated SGOT(140 IU/L), SGPT (228 IU/L), ALP (162IU/L), and blood urea(47 mg/ml) values. The patient was diagnosed to have developed Dytor plus induced toxic epidermal necrolysis. Discontinued the medicine and prescribed with Dexamethasone injection, IgG Injection, Cefotaxime injection, Cloxacilline capsule, Cetirizine tablet, Hydroxypropyl methylcellulose eye drop, and candid mouth paint. The patient had a hospital stay of 25 days.
Conclusions: The patient improved symptomatically. Causality was assessed as per the WHO-UMC causality scale and this case was put in the probable category. This case was uploaded via vigiflow under the pharmacovigilance programme of India having report Id 2019-30695.
Ancuceanu, R., Dinu, M., Furtunescu, F., & Boda, D. (2019). An inventory of medicinal products causing skin rash: Clinical and regulatory lessons. Experimental and therapeutic medicine, 18(6), 5061–5071.
Byrd, D. R., & Ahmed, I. (1997). Photosensitive lichenoid reaction to torsemide--a loop diuretic. Mayo Clinic proceedings, 72(10), 930–931.
DiPiro, J.T. (Ed.). (2002). Encyclopedia of Clinical Pharmacy (1st ed.). CRC Press. https://doi.org/10.1201/b13789
Dunn, C. J., Fitton, A., & Brogden, R. N. (1995). Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs, 49(1), 121–142.
Goodman & Gilman's, Manual of pharmacology and therapeutics, New York, Mc Graw Hill, 2008.
Greenblatt, D. J., & Koch-Weser, J. (1973). Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program. JAMA, 225(1), 40–43.
Kim, G. K., & Del Rosso, J. Q. (2012). Oral Spironolactone in Post-teenage Female Patients with Acne Vulgaris: Practical Considerations for the Clinician Based on Current Data and Clinical Experience. The Journal of clinical and aesthetic dermatology, 5(3), 37–50.
Mehta, B., Iyer, N., Iyer, C. M. (2016). Spironolactone‐ induced hypersensitivity in a patient with acne vulgaris. Indian journal of drugs in dermatology, 2(1), 40‐1.
Sundar, S., & Dickinson, P. D. (2012). Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate. BMJ case reports, 2012, bcr1120115238.
Vikas, S., Ramesh, M., Rani, V. N., Thennarasu, P. & Kannan, G. (2017). Incidence of diuretics induced adverse drug reactions in an intensive cardiac care unit of a tertiary care teaching hospital. International journal of pharmaceutical science and research, 8(8), 3557-3562.
Wang, Y., & Lipner, S. R. (2020). Retrospective analysis of adverse events with spironolactone in females reported to the United States Food and Drug Administration. International journal of women's dermatology, 6(4), 272–276.
Copyright (c) 2020 Melcy Mary Philip , Kala Kesavan P, Jai Prakash
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.